A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
DART-NK-SCLC
Phase 1/2 Recruiting
60 enrolled
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Phase 1/2 Recruiting
37 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
MK-6070-002
Phase 1/2 Recruiting
262 enrolled
MK-3475-01F
Phase 1/2 Recruiting
190 enrolled
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/2 Recruiting
428 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
KaRAnaSa
Phase 1/2 Recruiting
60 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Phase 1/2 Recruiting
45 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
DUO-NK-NSCLC
Phase 1/2 Recruiting
48 enrolled
Relapsed SCLC
Phase 1/2 Recruiting
166 enrolled
DURABLE
Phase 1/2 Recruiting
56 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
SNB-101-101
Phase 1/2 Recruiting
55 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2 Recruiting
188 enrolled
MARGARET
Phase 1/2 Recruiting
244 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
NAPISTAR1-01
Phase 1/2 Recruiting
250 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Phase 1/2 Recruiting
180 enrolled
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Phase 1/2 Recruiting
162 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Phase 1/2 Recruiting
251 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Phase 1/2 Recruiting
430 enrolled
MK-6070-003
Phase 1/2 Recruiting
170 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled